Search

Your search keyword '"Ames, Matthew"' showing total 663 results
Start Over Author "Ames, Matthew"
663 results on '"Ames, Matthew"'

1. The AECT Archives: Elusive Primary Sources, and Where to Find Them

Author

Clark-Stallkamp, Rebecca and Ames, Matthew

Abstract

Primary sources are the foundations of historical research because they are artifacts representing first-hand accounts or connections to the event, time, or place being investigated. The reality is that many IDT researchers do not have training in historical source analysis, nor do many researchers know where to find primary sources in the field of IDT, or how to conduct historical research if interested. Thus, this article retraces the history of the Association for Educational Communication and Technology's archive, and reveals where primary sources are located. The article details the history of the AECT archive to understand its significance in research. Next, a description on how to begin an archival visit, how archives function, and how to research within the archive is given -- including examples. Last, the authors discuss the importance of historical archive preservation and research to the field of IDT.

Published
2023
Full Text
View/download PDF

6. Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer

Author

Jayaraman, Swaathi, Wu, Xinyan, Kalari, Krishna R., Tang, Xiaojia, Kuffel, Mary J., Bruinsma, Elizabeth S., Jalali, Shahrzad, Peterson, Kevin L., Correia, Cristina, Kudgus, Rachel A., Kaufmann, Scott H., Renuse, Santosh, Ingle, James N., Reid, Joel M., Ames, Matthew M., Fields, Alan P., Schellenberg, Matthew J., Hawse, John R., Pandey, Akhilesh, and Goetz, Matthew P.

Published
2023
Full Text
View/download PDF

12. Upside and Downside Risk Exposures of Currency Carry Trades via Tail Dependence

Author

Ames, Matthew, Peters, Gareth W., Bagnarosa, Guillaume, and Kosmidis, Ioannis

Subjects
Quantitative Finance - Portfolio Management, Quantitative Finance - Risk Management
Abstract

Currency carry trade is the investment strategy that involves selling low interest rate currencies in order to purchase higher interest rate currencies, thus profiting from the interest rate differentials. This is a well known financial puzzle to explain, since assuming foreign exchange risk is uninhibited and the markets have rational risk-neutral investors, then one would not expect profits from such strategies. That is, according to uncovered interest rate parity (UIP), changes in the related exchange rates should offset the potential to profit from such interest rate differentials. However, it has been shown empirically, that investors can earn profits on average by borrowing in a country with a lower interest rate, exchanging for foreign currency, and investing in a foreign country with a higher interest rate, whilst allowing for any losses from exchanging back to their domestic currency at maturity. This paper explores the financial risk that trading strategies seeking to exploit a violation of the UIP condition are exposed to with respect to multivariate tail dependence present in both the funding and investment currency baskets. It will outline in what contexts these portfolio risk exposures will benefit accumulated portfolio returns and under what conditions such tail exposures will reduce portfolio returns., Comment: arXiv admin note: substantial text overlap with arXiv:1303.4314

Published
2014

13. Reinvestigating the Uncovered Interest Rate Parity Puzzle via Analysis of Multivariate Tail Dependence in Currency Carry Trades

Author

Ames, Matthew, Bagnarosa, Guillaume, and Peters, Gareth W.

Subjects
Quantitative Finance - Statistical Finance, Quantitative Finance - Portfolio Management
Abstract

The currency carry trade is the investment strategy that involves selling low interest rate currencies in order to purchase higher interest rate currencies, thus profiting from the interest rate differentials. This is a well known financial puzzle to explain, since assuming foreign exchange risk is uninhibited and the markets have rational risk-neutral investors, then one would not expect profits from such strategies. That is uncovered interest rate parity (UIP), the parity condition in which exposure to foreign exchange risk, with unanticipated changes in exchange rates, should result in an outcome that changes in the exchange rate should offset the potential to profit from such interest rate differentials. The two primary assumptions required for interest rate parity are related to capital mobility and perfect substitutability of domestic and foreign assets. Given foreign exchange market equilibrium, the interest rate parity condition implies that the expected return on domestic assets will equal the exchange rate-adjusted expected return on foreign currency assets. However, it has been shown empirically, that investors can actually earn arbitrage profits by borrowing in a country with a lower interest rate, exchanging for foreign currency, and investing in a foreign country with a higher interest rate, whilst allowing for any losses (or gains) from exchanging back to their domestic currency at maturity. Therefore trading strategies that aim to exploit the interest rate differentials can be profitable on average. The intention of this paper is therefore to reinterpret the currency carry trade puzzle in light of heavy tailed marginal models coupled with multivariate tail dependence features in the analysis of the risk-reward for the currency portfolios with high interest rate differentials and low interest rate differentials.

Published
2013

14. Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.

Author

Groshen, Susan, Sposto, Richard, Czarnecki, Scarlett, Ames, Matthew, Reynolds, C, Marachelian, Araz, Maurer, Barry, Kang, Min, Villablanca, Judith, Glade Bender, Julia, and Matthay, Katherine

Subjects
Acetaminophen, Ceftriaxone, Child, Dose-Response Relationship, Drug, Drug Interactions, Fatal Outcome, Fenretinide, Humans, Injections, Intravenous, Male, Neuroblastoma, Radiography
Abstract

BACKGROUND: Patients with relapsed/refractory stage 4 high-risk neuroblastoma were enrolled on a phase I study (NANT2004-03) of intravenous fenretinide emulsion. Pharmacokinetic samples were collected during and after the infusion, and the levels were measured using an HPLC system. A likely case of a fatal drug interaction between fenretinide, ceftriaxone, and acetaminophen is described, including the pharmacokinetics of fenretinide, laboratory data, and post-mortem autopsy in a pediatric neuroblastoma patient treated on this study. CASE PRESENTATION: On Day 4 of a scheduled 5-day-infusion of intravenous fenretinide, the patient developed a fever, acetaminophen was started, ceftriaxone initiated for possible bacteremia, and fenretinide level doubled from 56 to 110 μM. Over the next three days, although blood cultures remained negative, the patients condition deteriorated rapidly. Acute liver failure was diagnosed on Day 7, and the patient expired on Day 20 of fulminant hepatic failure with associated renal, cardiac, and hemorrhagic/coagulation toxicities. Autopsy showed extensive hemorrhagic necrosis of the liver, marked bile duct proliferation, and abundant hemosiderin, consistent with cholestasis and drug toxicity. CONCLUSIONS: After extensive review of patient data, the clinical course, and the literature, we conclude that observed hepatic toxicity was likely due to a drug interaction between fenretinide and concomitant ceftriaxone and acetaminophen. None of the other 16 patients treated on this study experienced significant hepatic toxicity. Although the prevalence of cholestasis with ceftriaxone usage is relatively high, the potential drug interaction with these concomitant medications has not been previously reported. Concomitant use of fenretinide, ceftriaxone, and acetaminophen should be avoided.

Published
2014

15. Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

Author

Lee, Eudocia Q, Puduvalli, Vinay K, Reid, Joel M, Kuhn, John G, Lamborn, Kathleen R, Cloughesy, Timothy F, Chang, Susan M, Drappatz, Jan, Yung, WK Alfred, Gilbert, Mark R, Robins, H Ian, Lieberman, Frank S, Lassman, Andrew B, McGovern, Renee M, Xu, Jihong, Desideri, Serena, Ye, Xiabu, Ames, Matthew M, Espinoza-Delgado, Igor, Prados, Michael D, and Wen, Patrick Y

Subjects
Brain Disorders, Orphan Drug, Rare Diseases, Cancer, Brain Cancer, Neurosciences, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Dacarbazine, Female, Glioma, Humans, Hydroxamic Acids, Male, Middle Aged, Neoplasm Grading, Temozolomide, Treatment Outcome, Vorinostat, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeA phase I, dose-finding study of vorinostat in combination with temozolomide (TMZ) was conducted to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics in patients with high-grade glioma (HGG).Experimental designThis phase I, dose-finding, investigational study was conducted in two parts. Part 1 was a dose-escalation study of vorinostat in combination with TMZ 150 mg/m(2)/day for 5 days every 28 days. Part 2 was a dose-escalation study of vorinostat in combination with TMZ 150 mg/m(2)/day for 5 days of the first cycle and 200 mg/m(2)/day for 5 days of the subsequent 28-day cycles.ResultsIn part 1, the MTD of vorinostat administered on days 1 to 7 and 15 to 21 of every 28-day cycle, in combination with TMZ, was 500 mg daily. Dose-limiting toxicities (DLT) included grade 3 anorexia, grade 3 ALT, and grade 5 hemorrhage in the setting of grade 4 thrombocytopenia. In part 2, the MTD of vorinostat on days 1 to 7 and 15 to 21 of every 28-day cycle, combined with TMZ, was 400 mg daily. No DLTs were encountered, but vorinostat dosing could not be escalated further due to thrombocytopenia. The most common serious adverse events were fatigue, lymphopenia, thrombocytopenia, and thromboembolic events. There were no apparent pharmacokinetic interactions between vorinostat and TMZ. Vorinostat treatment resulted in hyperacetylation of histones H3 and H4 in peripheral mononuclear cells.ConclusionVorinostat in combination with temozolomide is well tolerated in patients with HGG. A phase I/II trial of vorinostat with radiotherapy and concomitant TMZ in newly diagnosed glioblastoma is underway.

Published
2012

21. Supplementary Figure S2 from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention

Author

Ingle, James N., primary, Liu, Mohan, primary, Wickerham, D. Lawrence, primary, Schaid, Daniel J., primary, Wang, Liewei, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Costantino, Joseph P., primary, Vogel, Victor G., primary, Paik, Soonmyung, primary, Goetz, Matthew P., primary, Ames, Matthew M., primary, Jenkins, Gregory D., primary, Batzler, Anthony, primary, Carlson, Erin E., primary, Flockhart, David A., primary, Wolmark, Norman, primary, Nakamura, Yusuke, primary, and Weinshilboum, Richard M., primary

Published
2023
Full Text
View/download PDF

22. Perspectives on This Article from Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668

Author

Reid, Joel M., primary, Walden, Chad A., primary, Qin, Rui, primary, Ziegler, Katie L. Allen, primary, Haslam, John L., primary, Rajewski, Roger A., primary, Warndahl, Roger, primary, Fitting, Cindy L., primary, Boring, Daniel, primary, Szabo, Eva, primary, Crowell, James, primary, Perloff, Marjorie, primary, Jong, Ling, primary, Bauer, Brent A., primary, Mandrekar, Sumithra J., primary, Ames, Matthew M., primary, and Limburg, Paul J., primary

Published
2023
Full Text
View/download PDF

23. Data from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention

Author

Ingle, James N., primary, Liu, Mohan, primary, Wickerham, D. Lawrence, primary, Schaid, Daniel J., primary, Wang, Liewei, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Costantino, Joseph P., primary, Vogel, Victor G., primary, Paik, Soonmyung, primary, Goetz, Matthew P., primary, Ames, Matthew M., primary, Jenkins, Gregory D., primary, Batzler, Anthony, primary, Carlson, Erin E., primary, Flockhart, David A., primary, Wolmark, Norman, primary, Nakamura, Yusuke, primary, and Weinshilboum, Richard M., primary

Published
2023
Full Text
View/download PDF

24. Data from Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668

Author

Reid, Joel M., primary, Walden, Chad A., primary, Qin, Rui, primary, Ziegler, Katie L. Allen, primary, Haslam, John L., primary, Rajewski, Roger A., primary, Warndahl, Roger, primary, Fitting, Cindy L., primary, Boring, Daniel, primary, Szabo, Eva, primary, Crowell, James, primary, Perloff, Marjorie, primary, Jong, Ling, primary, Bauer, Brent A., primary, Mandrekar, Sumithra J., primary, Ames, Matthew M., primary, and Limburg, Paul J., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Material from Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention

Author

Ingle, James N., primary, Liu, Mohan, primary, Wickerham, D. Lawrence, primary, Schaid, Daniel J., primary, Wang, Liewei, primary, Mushiroda, Taisei, primary, Kubo, Michiaki, primary, Costantino, Joseph P., primary, Vogel, Victor G., primary, Paik, Soonmyung, primary, Goetz, Matthew P., primary, Ames, Matthew M., primary, Jenkins, Gregory D., primary, Batzler, Anthony, primary, Carlson, Erin E., primary, Flockhart, David A., primary, Wolmark, Norman, primary, Nakamura, Yusuke, primary, and Weinshilboum, Richard M., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 2 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Author

Holkova, Beata, primary, Supko, Jeffrey G., primary, Ames, Matthew M., primary, Reid, Joel M., primary, Shapiro, Geoffrey I., primary, Perkins, Edward Brent, primary, Ramakrishnan, Viswanathan, primary, Tombes, Mary Beth, primary, Honeycutt, Connie, primary, McGovern, Renee M., primary, Kmieciak, Maciej, primary, Shrader, Ellen, primary, Wellons, Martha D., primary, Sankala, Heidi, primary, Doyle, Austin, primary, Wright, John, primary, Roberts, John D., primary, and Grant, Steven, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 3 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Author

Holkova, Beata, primary, Supko, Jeffrey G., primary, Ames, Matthew M., primary, Reid, Joel M., primary, Shapiro, Geoffrey I., primary, Perkins, Edward Brent, primary, Ramakrishnan, Viswanathan, primary, Tombes, Mary Beth, primary, Honeycutt, Connie, primary, McGovern, Renee M., primary, Kmieciak, Maciej, primary, Shrader, Ellen, primary, Wellons, Martha D., primary, Sankala, Heidi, primary, Doyle, Austin, primary, Wright, John, primary, Roberts, John D., primary, and Grant, Steven, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 1 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Author

Holkova, Beata, primary, Supko, Jeffrey G., primary, Ames, Matthew M., primary, Reid, Joel M., primary, Shapiro, Geoffrey I., primary, Perkins, Edward Brent, primary, Ramakrishnan, Viswanathan, primary, Tombes, Mary Beth, primary, Honeycutt, Connie, primary, McGovern, Renee M., primary, Kmieciak, Maciej, primary, Shrader, Ellen, primary, Wellons, Martha D., primary, Sankala, Heidi, primary, Doyle, Austin, primary, Wright, John, primary, Roberts, John D., primary, and Grant, Steven, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 2 from Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

Author

Lee, Eudocia Q., primary, Puduvalli, Vinay K., primary, Reid, Joel M., primary, Kuhn, John G., primary, Lamborn, Kathleen R., primary, Cloughesy, Timothy F., primary, Chang, Susan M., primary, Drappatz, Jan, primary, Yung, W. K. Alfred, primary, Gilbert, Mark R., primary, Robins, H. Ian, primary, Lieberman, Frank S., primary, Lassman, Andrew B., primary, McGovern, Renee M., primary, Xu, Jihong, primary, Desideri, Serena, primary, Ye, Xiabu, primary, Ames, Matthew M., primary, Espinoza-Delgado, Igor, primary, Prados, Michael D., primary, and Wen, Patrick Y., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Methods from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Author

Holkova, Beata, primary, Supko, Jeffrey G., primary, Ames, Matthew M., primary, Reid, Joel M., primary, Shapiro, Geoffrey I., primary, Perkins, Edward Brent, primary, Ramakrishnan, Viswanathan, primary, Tombes, Mary Beth, primary, Honeycutt, Connie, primary, McGovern, Renee M., primary, Kmieciak, Maciej, primary, Shrader, Ellen, primary, Wellons, Martha D., primary, Sankala, Heidi, primary, Doyle, Austin, primary, Wright, John, primary, Roberts, John D., primary, and Grant, Steven, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 1 from Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

Author

Lee, Eudocia Q., primary, Puduvalli, Vinay K., primary, Reid, Joel M., primary, Kuhn, John G., primary, Lamborn, Kathleen R., primary, Cloughesy, Timothy F., primary, Chang, Susan M., primary, Drappatz, Jan, primary, Yung, W. K. Alfred, primary, Gilbert, Mark R., primary, Robins, H. Ian, primary, Lieberman, Frank S., primary, Lassman, Andrew B., primary, McGovern, Renee M., primary, Xu, Jihong, primary, Desideri, Serena, primary, Ye, Xiabu, primary, Ames, Matthew M., primary, Espinoza-Delgado, Igor, primary, Prados, Michael D., primary, and Wen, Patrick Y., primary

Published
2023
Full Text
View/download PDF

35. Data from Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

Author

Kummar, Shivaani, primary, Chen, Alice, primary, Ji, Jiuping, primary, Zhang, Yiping, primary, Reid, Joel M., primary, Ames, Matthew, primary, Jia, Lee, primary, Weil, Marcie, primary, Speranza, Giovanna, primary, Murgo, Anthony J., primary, Kinders, Robert, primary, Wang, Lihua, primary, Parchment, Ralph E., primary, Carter, John, primary, Stotler, Howard, primary, Rubinstein, Larry, primary, Hollingshead, Melinda, primary, Melillo, Giovanni, primary, Pommier, Yves, primary, Bonner, William, primary, Tomaszewski, Joseph E., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 1 from Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

Author

Kummar, Shivaani, primary, Chen, Alice, primary, Ji, Jiuping, primary, Zhang, Yiping, primary, Reid, Joel M., primary, Ames, Matthew, primary, Jia, Lee, primary, Weil, Marcie, primary, Speranza, Giovanna, primary, Murgo, Anthony J., primary, Kinders, Robert, primary, Wang, Lihua, primary, Parchment, Ralph E., primary, Carter, John, primary, Stotler, Howard, primary, Rubinstein, Larry, primary, Hollingshead, Melinda, primary, Melillo, Giovanni, primary, Pommier, Yves, primary, Bonner, William, primary, Tomaszewski, Joseph E., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Information, Figure 1 from Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent

Author

Patra, Chitta Ranjan, primary, Bhattacharya, Resham, primary, Wang, Enfeng, primary, Katarya, Aaron, primary, Lau, Julie S., primary, Dutta, Shamit, primary, Muders, Michael, primary, Wang, Shanfeng, primary, Buhrow, Sarah A., primary, Safgren, Stephanie L., primary, Yaszemski, Michael J., primary, Reid, Joel M., primary, Ames, Matthew M., primary, Mukherjee, Priyabrata, primary, and Mukhopadhyay, Debabrata, primary

Published
2023
Full Text
View/download PDF

39. Data from Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent

Author

Patra, Chitta Ranjan, primary, Bhattacharya, Resham, primary, Wang, Enfeng, primary, Katarya, Aaron, primary, Lau, Julie S., primary, Dutta, Shamit, primary, Muders, Michael, primary, Wang, Shanfeng, primary, Buhrow, Sarah A., primary, Safgren, Stephanie L., primary, Yaszemski, Michael J., primary, Reid, Joel M., primary, Ames, Matthew M., primary, Mukherjee, Priyabrata, primary, and Mukhopadhyay, Debabrata, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Methods, Tables 1-2, Figure Legend from Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

Author

Kummar, Shivaani, primary, Chen, Alice, primary, Ji, Jiuping, primary, Zhang, Yiping, primary, Reid, Joel M., primary, Ames, Matthew, primary, Jia, Lee, primary, Weil, Marcie, primary, Speranza, Giovanna, primary, Murgo, Anthony J., primary, Kinders, Robert, primary, Wang, Lihua, primary, Parchment, Ralph E., primary, Carter, John, primary, Stotler, Howard, primary, Rubinstein, Larry, primary, Hollingshead, Melinda, primary, Melillo, Giovanni, primary, Pommier, Yves, primary, Bonner, William, primary, Tomaszewski, Joseph E., primary, and Doroshow, James H., primary

Published
2023
Full Text
View/download PDF

49. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic‐based dosing of irinotecan, oxaliplatin, and capecitabine as first‐line therapy for patients with advanced small bowel adenocarcinoma

Author

McWilliams, Robert R., Foster, Nathan R., Mahoney, Michelle R., Smyrk, Thomas C., Murray, Joseph A., Ames, Matthew M., Horvath, L. Elise, Schneider, Daniel J., Hobday, Timothy J., Jatoi, Aminah, Meyers, Jeffrey P., and Goetz, Matthew P.

Published
2017
Full Text
View/download PDF

50. Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies

Author

Goetz, Matthew P., Sun, James X., Suman, Vera J., Silva, Grace O., Perou, Charles M., Nakamura, Yusuke, Cox, Nancy J., Stephens, Philip J., Miller, Vincent A., Ross, Jeffrey S., Chen, David, Safgren, Stephanie L., Kuffel, Mary J., Ames, Matthew M., Kalari, Krishna R., Gomez, Henry L., Gonzalez-Angulo, Ana M., Burgues, Octavio, Brauch, Hiltrud B., Ingle, James N., Ratain, Mark J., and Yelensky, Roman

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results